

1  
2  
3  
4 **1 Short “infraslow” activity (SISA) with burst suppression in acute anoxic**  
5  
6  
7 **2 encephalopathy: a rare, specific ominous sign with acute post-hypoxic myoclonus or**  
8  
9  
10 **3 acute symptomatic seizures**

4

17 5 Masaya Togo MD<sup>1</sup>, Takefumi Hitomi MD PhD<sup>1, 2</sup>, Tomohiko Murai MD<sup>1</sup>,  
18  
19  
20  
21 6 Hajime Yoshimura MD PhD<sup>3</sup>, Masao Matsubishi MD PhD<sup>4</sup>, Riki Matsumoto  
22  
23  
24 7 MD PhD<sup>1</sup>, Michi Kawamoto MD<sup>3</sup>, Nobuo Kohara MD PhD<sup>3</sup>, Ryosuke  
25  
26  
27  
28 8 Takahashi MD PhD<sup>1</sup>, Akio Ikeda MD PhD<sup>5</sup>

9

35 10 1 Department of Neurology, Kyoto University Graduate School of Medicine,  
36  
37  
38 11 Japan

42 12 2 Department of Clinical Laboratory Medicines, Kyoto University Graduate  
43  
44  
45 13 School of Medicine, Japan

49 14 3 Department of Neurology, Kobe City Medical Center General Hospital,  
50  
51  
52 15 Japan

56 16 4 Human Brain Research Center, Kyoto University Graduate School of

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

17 Medicine, Japan

18 5 Department of Epilepsy, Movement Disorders and Physiology, Kyoto

19 University Graduate School of Medicine, Japan

20

21

22 Corresponding author:

23 Akio Ikeda MD, PhD

24 Department of Epilepsy, Movement Disorders and Physiology, Kyoto

25 University Graduate University School of Medicine

26 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan

27 E-mail: akio@kuhp.kyoto-u.ac.jp

28

29

30 Co-corresponding author:

31 Takefumi Hitomi MD, PhD

32 Department of Clinical Laboratory Medicine, Kyoto University Graduate

1  
2  
3 33 University School of Medicine, Japan  
4  
5

6  
7 34 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan  
8  
9

10 35 Email: hitomi46@kuhp.kyoto-u.ac.jp  
11  
12

13  
14 36  
15

16  
17 37 **Conflicts of Interest and Source of Funding**  
18  
19

20  
21 38 The Department of Epilepsy, Movement Disorders and Physiology is an  
22  
23  
24 39 endowment department, supported with a grant from GlaxoSmithKline K.K., Nihon  
25  
26  
27  
28 40 Kohden Corporation, Otsuka Pharmaceutical Co., and UCB Japan Co., Ltd.  
29  
30

31 41 TH reports grants from the Japan Ministry of Education, Culture, Sports,  
32  
33  
34  
35 42 Science and Technology (MEXT), KAKENHI 17K09798 and the Kyoto University  
36  
37  
38  
39 43 Research Fund for Senior Scientists during the conduct of the study; and personal fees  
40  
41  
42 44 from Nihon Kohden Corporation, other funding from UCB Japan Co., Ltd., other funding  
43  
44  
45 45 from Eisei Co., Ltd., outside the submitted work.  
46  
47

48 46 RM reports grants from MEXT, KAKENHI 26282218, 15H01664, and  
49  
50  
51  
52 47 15H05874 during the conduct of the study.  
53  
54  
55

56 48 AI reports grants from MEXT, KAKENHI 15H05874 and Japan Society for the  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 49 Promotion of Science (JSPS) KAKENHI 26293209, 26462223, 25350691, 23500484  
4  
5  
6  
7 50 during the conduct of the study; and personal fees from UCB Japan, personal fees from  
8  
9  
10 51 GlaxoSmithKline K.K., personal fees from Otsuka Pharmaceutical Co., Ltd., personal  
11  
12  
13  
14 52 fees from Daiichi Sankyo Company, Ltd, personal fees from Novartis Pharma K.K.,  
15  
16  
17 53 personal fees from Eisai Co., Ltd., grants from Kyowa Hakko Kirin Co., Ltd., personal  
18  
19  
20  
21 54 fees from Kyowa Hakko Kirin Co., Ltd., personal fees from Kowa Pharmaceutical Co.  
22  
23  
24 55 Ltd., other from GlaxoSmithKline K.K., other from Nihon Kohden Corporation, other  
25  
26  
27  
28 56 from Otsuka Pharmaceutical Co., and other from UCB Japan Co., Ltd., outside the  
29  
30  
31 57 submitted work.  
32  
33  
34  
35 58  
36  
37  
38  
39 59 **Meetings in which the paper has been presented**  
40  
41  
42 60 The 57<sup>th</sup> Annual meetings of the Japanese Society of Neurology  
43  
44  
45 61 The 50<sup>th</sup> Congress of the Japan Epilepsy Society  
46  
47  
48  
49 62  
50  
51  
52  
53 63 Running title  
54  
55  
56 64 Infraslow activity in acute anoxic encephalopathy  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

65

66 Words count

67 Abstract = 250 words, Paper = 3286 words

68 **ABSTRACT**

69 **Objective:** Slow wave with frequency  $<0.5$  Hz are recorded in various situations such as  
70 normal sleep, epileptic seizures. However, its clinical significance has not been fully  
71 clarified. Although infraslow activity was recently defined as activity between 0.01 and  
72 0.1Hz, we focus on the activity recorded with time constant of 2 s for practical usage. We  
73 defined short “infraslow” activity (SISA) less than 0.5 Hz recorded with time constant of  
74 2 s and investigated the occurrence and clinical significance of SISA in acute anoxic  
75 encephalopathy.

76 **Methods:** This study evaluated findings of electroencephalography (EEG) in consecutive  
77 98 comatose patients with acute anoxic encephalopathy after cardiac arrest. We first  
78 classified EEG findings conventionally, then investigated SISA by time constant of 2 s  
79 and a high-cut filter of 120 Hz, to clarify the relationship between SISA and clinical  
80 profiles especially of clinical outcomes and occurrence of acute post-hypoxic myoclonus  
81 or acute symptomatic seizures.

82 **Results:** SISA was found in 6 patients (6.2%), superimposed on the burst phase of the  
83 burst-suppression pattern. All 6 patients showed acute post-hypoxic myoclonus or acute

1  
2  
3 84 symptomatic seizures (generalized tonic-clonic seizures) and its prognosis was poor. This  
4  
5  
6  
7 85 100% occurrence of acute post-hypoxic myoclonus or acute symptomatic seizures was  
8  
9  
10 86 significantly higher than that in patients without SISA (39.1%;  $P < 0.05$ ).

11  
12  
13 87 **Conclusions:** SISA in acute anoxic encephalopathy could be associated with acute post-  
14  
15  
16  
17 88 hypoxic myoclonus and acute symptomatic seizures. SISA could be a practically feasible  
18  
19  
20  
21 89 biomarker for myoclonus or seizures and poor prognosis in acute anoxic encephalopathy,  
22  
23  
24 90 if it occurs with burst suppression.

25  
26  
27  
28 91  
29  
30  
31 92 **Keywords:** short infraslow activity; anoxic encephalopathy; burst-suppression; acute  
32  
33  
34  
35 93 symptomatic seizure  
36

37  
38 94 **Abbreviations**

39  
40  
41  
42 95 CPC: Cerebral Performance Category, EEG: electroencephalograms, FFT: fast Fourier  
43  
44  
45  
46 96 transform, SISA: short infraslow activity  
47

48  
49 97  
50

51  
52  
53 98  
54

55  
56 99  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 100  
4  
5  
67 101 **1. INTRODUCTION**  
8  
910 102 The outcomes of acute anoxic encephalopathy after cardiac arrest are generally  
11  
1213  
14 103 very poor, with only 15-20% achieving good prognosis,<sup>1</sup> and about 50% never regaining  
15  
1617 104 consciousness after resuscitation.<sup>2,3</sup> Precise prediction of neurological disabilities or acute  
18  
1920  
21 105 symptomatic seizures in these patients is important, since these factors are crucial for the  
22  
2324 106 prognosis and decisions of therapeutic intervention. Electroencephalography (EEG) is  
25  
2627 107 still one of the most useful examinations in patients with acute anoxic encephalopathy.  
28  
2930  
31 108 Background suppression, burst suppression, epileptiform discharges and generalized  
32  
3334  
35 109 periodic discharges have been reported as poor prognostic factors.<sup>4,5,6</sup> Clinical  
36  
3738 110 manifestations of myoclonic status epilepticus, absence of pupillary light responses,  
39  
4041  
42 111 corneal reflexes and motor responses to pain have also been associated with poor  
43  
4445 112 outcomes.<sup>4,5</sup> However, the relationships between other patterns on EEG and prognosis or  
46  
4748  
49 113 acute symptomatic seizure have not yet been fully clarified.  
50  
5152 114 Very slow EEG activity with frequency <0.5 Hz has been reported in previous  
53  
5455  
56 115 studies. The exact generators of this activity remain unknown, but have been presumed  
57  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3 116 to involve the function of astrocytes,<sup>7</sup> with spontaneous slow oscillating activity of  
4  
5  
6  
7 117 astrocytes seen in an in-vitro study,<sup>8</sup> and voltage differences produced by the function of  
8  
9  
10 118 the blood-brain barrier identified in another study.<sup>9</sup> Some researchers have recorded very  
11  
12  
13  
14 119 slow EEG activity from electrocorticography<sup>10-12</sup> and even from scalp-recorded EEG in  
15  
16  
17 120 epilepsy, brain ischemia and normal sleep.<sup>13,14</sup>

21 121 In terms of clinical significance, previous studies have shown that ictal  
22  
23  
24 122 infraslow activity could contribute to delineation of the core epileptogenic area in human  
25  
26  
27  
28 123 intractable epilepsy.<sup>10,11</sup> Another study showed infraslow activity (0.015-0.06 Hz) present  
29  
30  
31 124 in acute anoxic encephalopathy, with larger-amplitude activity only observed in patients  
32  
33  
34  
35 125 with poor outcomes.<sup>15</sup> However, whether such activity emerges in other clinical situations  
36  
37  
38 126 is unclear, and the clinical significance of infraslow activity has not been clarified. In  
39  
40  
41  
42 127 addition, filter settings have varied among studies ranging from 0.01 to 0.1 Hz,<sup>15</sup> and the  
43  
44  
45  
46 128 degree of infraslow activity in other frequency bands remains unknown.

49 129 The definition of infraslow activity has also been variable. Aladjalova first  
50  
51  
52  
53 130 recorded rhythms with frequencies of 0.01-0.1Hz from the neocortex of rabbits in 1957.<sup>16</sup>  
54  
55  
56 131 Vanhatalo et al. defined a frequency range between 0.0 Hz and 0.2 Hz as infraslow  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 132 oscillations (ISOs).<sup>14,17</sup> Thordstein et al.<sup>18</sup> showed 0.05- to 70-Hz activity in post-  
4  
5  
6  
7 133 asphyctic full-term neonates, and termed 0- to 1-Hz activity as very low-frequency  
8  
9  
10 134 activity (VLFA).<sup>18</sup> Rodin et al. and other researchers have used 0.01-0.1 Hz and 0.01-0.5  
11  
12  
13  
14 135 Hz,<sup>19-22</sup> but reported 0.1- to 0.9-Hz activities as cerebral electromagnetic activity in the  
15  
16  
17 136 subdelta range.<sup>23</sup> The definition of 0.01-0.1 Hz has seen frequent use in recent years.<sup>15,24-</sup>  
18  
19  
20  
21 137 <sup>26</sup> However, some studies have used other definitions, such as 0.07-100 Hz.<sup>27</sup> In short,  
22  
23  
24 138 infraslow activity was defined recently as rhythms with frequencies of 0.01-0.1 Hz. The  
25  
26  
27  
28 139 present study focused on rhythms with frequencies >0.08 Hz (time constant, 2 s), since  
29  
30  
31 140 such activity is easily confirmed in clinical situations. However, the frequency band of  
32  
33  
34  
35 141 the activity is larger than the recently reported values for infraslow activity<sup>15,24-26</sup> We  
36  
37  
38  
39 142 therefore use the term “short infraslow activity (SISA)” for activity between 0.08 and 0.5  
40  
41  
42 143 Hz in this article, to distinguish such activity from “infraslow activity”.

44  
45 144 The aim of the present work was to investigate whether SISA was observed in  
46  
47  
48  
49 145 acute anoxic encephalopathy. If present, we aimed to investigate the relationship between  
50  
51  
52  
53 146 this activity and clinical profiles such as prognosis and acute symptomatic seizures.  
54  
55

56 147  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 148 **2. METHODS**  
4  
5

6  
7 149 **2.1. Patients**  
8  
9

10 150 Patient characteristics are presented in Table 1. We retrospectively analyzed  
11  
12  
13  
14 151 records of EEG for 98 consecutive acute comatose patients (71 males, 27 females; mean  
15  
16  
17 152 ( $\pm$  standard deviation) age,  $65.7 \pm 15.4$  years) from acute anoxic encephalopathy. All  
18  
19  
20  
21 153 EEGs were recorded in an intensive care unit after successful resuscitation from cardiac  
22  
23  
24 154 arrest. Two patients (one <18 years old, one with acute stroke) were excluded. Among  
25  
26  
27  
28 155 the 98 records of EEG, 40 were recorded at Kyoto University Hospital between April  
29  
30  
31 156 2008 and September 2015, and 58 were recorded at Kobe City Medical Center General  
32  
33  
34  
35 157 Hospital between January 2012 and September 2015.  
36  
37

38 158 Thirty-six patients (36.7%) experienced in-hospital cardiac arrest. Acute post-  
39  
40  
41  
42 159 hypoxic myoclonus<sup>28</sup> and acute symptomatic seizures occurred in 42 patients (42.8%).  
43  
44  
45 160 Among 42 patients with acute post-hypoxic myoclonus or acute symptomatic seizures,  
46  
47  
48  
49 161 37 patients showed acute post-hypoxic myoclonus alone, 2 patients had generalized  
50  
51  
52  
53 162 tonic-clonic seizures alone, and 3 patients had both. As for treatment, all patients were  
54  
55  
56 163 treated according to the standard protocols for acute anoxic encephalopathy. In addition,  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 164 29 patients (29.6%) received mild therapeutic hypothermia in the first 24 h, reducing the  
4  
5  
6  
7 165 body temperature to 34°C with a cooling pad and then rewarming to normothermia.  
8  
9  
10 166 Propofol and fentanyl were also used for sedation and to prevent shivering until body  
11  
12  
13  
14 167 temperature had reached normothermia. The primary outcome measure was  
15  
16  
17 168 neurological outcome, expressed as the score for the Cerebral Performance Category  
18  
19  
20  
21 169 (CPC)<sup>29,30</sup> after 3 months. Good neurological outcome was defined as a CPC score of 1  
22  
23  
24  
25 170 or 2 (no or moderate disability, respectively), and poor neurological outcome was  
26  
27  
28 171 defined as a score of 3, 4, or 5 (severely disabled, comatose, or deceased, respectively).  
29  
30  
31 172 In the present study, only 6 patients (6.1%) achieved good outcomes (CPC score of 1 or  
32  
33  
34  
35 173 2) among the 98 patients (Table 1).  
36  
37  
38  
39 174

## 42 175 **2.2 Recordings from EEG**

45 176 Scalp-recorded EEG was obtained in the conventional manner with a  
47  
48  
49 177 multichannel EEG machine (Nihon Kohden, Tokyo, Japan) using 21 Ag-AgCl  
50  
51  
52  
53 178 electrodes with the International 10-20 system. EEGs were recorded for at least 20 min.  
54  
55  
56 179 The sampling rate was set at 500 Hz and the time constant was 2 s. EEG was recorded  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 180 from 4 h to 8 days (mean,  $2.4 \pm 1.6$  days) after resuscitation, and was recorded during  
4  
5  
6  
7 181 mild therapeutic hypothermia in 14 cases. EEGs were recorded at 8 days in three  
8  
9  
10 182 patients, and at 6 days in two patients after cardiopulmonary arrest. The remaining  
11  
12  
13  
14 183 patients (94.9%) underwent EEG recording within 5 days after cardiopulmonary arrest.  
15  
16  
17 184 Artifacts were monitored and electromyographic artifacts were eliminated by  
18  
19  
20  
21 185 neuromuscular blockade in some patients.  
22  
23  
24  
25 186

### 27 187 **2.3. EEG analysis**

28  
29  
30  
31 188 For this study, each EEG was visually analyzed in the conventional manner by  
32  
33  
34  
35 189 two certified electroencephalographers blinded to clinical data. EEGs were analyzed  
36  
37  
38  
39 190 with a sensitivity of 2-10  $\mu\text{V}/\text{mm}$ . One record of EEG was excluded from analysis due  
40  
41  
42 191 to abundant artifacts on EEG. We therefore employed 97 records of EEG from 98  
43  
44  
45  
46 192 patients.  
47  
48

49 193 First, we conventionally classified EEG patterns into 9 categories  
50  
51  
52 194 (electrocerebral inactivity, background suppression, burst suppression, periodic  
53  
54  
55  
56 195 discharge, delta coma, alpha coma, diffuse slowing, spindle coma and normal).  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 196 Electrocerebral inactivity, background suppression, burst suppression and periodic  
4  
5  
6  
7 197 discharge were supposed to be associated with poor prognosis according to previous  
8  
9  
10 198 studies.<sup>2,31,32</sup> In addition, burst-suppression pattern was divided into two subtypes  
11  
12  
13  
14 199 depending on whether the identical bursts occurred. “Burst-suppression with identical  
15  
16  
17 200 bursts” was considered present if the shapes of the bursts in the first 500 ms were  
18  
19  
20  
21 201 identical;<sup>33</sup> otherwise, we considered the pattern as “Burst-suppression without identical  
22  
23  
24 202 bursts”.

25  
26  
27  
28 203           Second, SISA was displayed and evaluated in a referential or average montage  
29  
30  
31 204 using a time constant of 2 s and a high-cut filter of 120 Hz. SISA was defined as sustained  
32  
33  
34  
35 205 negative and/or positive potentials lasting >3 s, as in the previously described method  
36  
37  
38  
39 206 with the following modification for practical usage in clinical situations<sup>10,12</sup>: peak-to-peak  
40  
41  
42 207 amplitude >10  $\mu$ V in a 1-min epoch as an operational definition in this study. We checked  
43  
44  
45 208 the reproducibility of SISA with regard to location, waveform, duration, and amplitude  
46  
47  
48  
49 209 within each patient. We carefully distinguished artifacts of slower frequency such as  
50  
51  
52  
53 210 respiratory or body movements by visual analysis of simultaneous video, EEG and  
54  
55  
56 211 electromyogram (EMG) recordings and time-frequency analysis of EEG. The fast Fourier  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 212 transform (FFT) module was applied for time-frequency analysis in order to evaluate  
4  
5  
6  
7 213 EMG artifacts, which suggest body movements.  
8  
9

10 214 We also calculated mean and standard deviation of parameters of SISA: interval,  
11  
12  
13  
14 215 duration, frequency of burst phase coinciding with SISA and amplitude within each  
15  
16  
17 216 patient. The definition of parameters of SISA (namely the onset, end, duration and  
18  
19  
20  
21 217 amplitude) were almost the same as in our previous work.<sup>12</sup> The onset of SISA was  
22  
23  
24 218 defined as the onset of the beginning of the earliest negative slow shift. The end of SISA  
25  
26  
27  
28 219 was defined as the inflection point at the end of the negative slow shift. The duration was  
29  
30  
31 220 defined as the interval between the onset and end. The amplitude was defined as the  
32  
33  
34  
35 221 absolute maximum difference between onset and the next peak of the shift, usually with  
36  
37  
38  
39 222 the largest excursion from onset. We measured the duration and amplitude of SISA using  
40  
41  
42 223 software produced by Nihon Kohden.  
43  
44

45 224 The ethics committee of the two hospitals approved the entire protocol as a  
46  
47  
48  
49 225 retrospective study.  
50  
51

52  
53 226

54  
55  
56 227 **2.4. Statistical analysis**  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 228 We analyzed: 1) the occurrence rate of acute post-hypoxic myoclonus or acute  
4  
5  
6  
7 229 symptomatic seizures; and 2) the rate of good outcomes (CPC score 1 or 2) in both  
8  
9  
10 230 patients with SISA and patients without SISA. For statistical analysis, we used Fisher's  
11  
12  
13  
14 231 exact test. Values of  $P < 0.05$  were considered statistically significant.  
15  
16

17 232

### 21 233 **3. RESULTS**

#### 24 234 **3.1. Findings from conventional EEG**

27 235 EEG findings are summarized in Table 2. All patients showed abnormalities on  
28  
29  
30  
31 236 EEG. Findings suggestive of poor prognosis (electrocerebral inactivity, background  
32  
33  
34  
35 237 suppression, burst suppression and periodic discharge) were identified in 48 patients  
36  
37  
38 238 (49.0%).  
39  
40  
41

42 239

#### 45 240 **3.2. SISA**

47  
48  
49 241 We found SISA in only 6 of 97 patients (6.2%). All these instances represented  
50  
51  
52 242 generalized activity and occurred during the burst period of burst-suppression. In this  
53  
54  
55  
56 243 study, all patients with burst suppression displayed SISA. No patients with electrocerebral  
57  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3 244 inactivity showed SISA. The duration of negative SISA (negative duration) ranged from  
4  
5  
6  
7 245 3 to 10 s (Figure 1A, B). Three patients showed a burst-suppression pattern with identical  
8  
9  
10 246 burst (Table 3). The intervals of infraslow activities varied among patients, ranging from  
11  
12  
13  
14 247 5 s to 50 s (Table 4). Although the so-called “burst” period with SISA mainly involved  
15  
16  
17 248 theta (4-7 Hz) and alpha (8-13 Hz) activity, delta-range activity (3-4 Hz) was also seen  
18  
19  
20  
21 249 (Table 4). Time-frequency analysis of EEG revealed that the frequency of fast activity on  
22  
23  
24  
25 250 SISA was <50 Hz and also revealed no electromyographic artifacts (Figure 1C).  
26  
27

28 251 All 6 patients with SISA showed acute post-hypoxic myoclonus or acute  
29  
30  
31 252 symptomatic seizures (Table 3). Five patients showed acute post-hypoxic myoclonus of  
32  
33  
34  
35 253 the whole body, 1 patient experienced generalized tonic-clonic seizures and 1 patient had  
36  
37  
38  
39 254 both. Three patients died during hospitalization and no neurological improvements (CPC  
40  
41  
42 255 score 4) were seen in the remaining 3 patients (Table 3). The occurrence rate of acute  
43  
44  
45  
46 256 post-hypoxic myoclonus and acute symptomatic seizures in patients with SISA (100%)  
47  
48  
49 257 was significantly higher than in patients without SISA (39.1%) (Fisher’s exact test,  $P =$   
50  
51  
52  
53 258 0.0067, sensitivity = 13.6%, specificity = 100%) (Table 5), although the prognosis did not  
54  
55  
56 259 differ significantly between patients with SISA and those without SISA (Fisher’s exact  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 260 test,  $P = 0.68$ , sensitivity = 6.5%, specificity = 100%) (Table 5).  
4  
5  
6

7 261  
8  
9

#### 10 262 **4. DISCUSSION** 11 12

13  
14 263 The present study found that SISA with a negative duration of 3-10 s occurred  
15  
16  
17 264 infrequently during acute anoxic encephalopathy (6.2%). All SISA coincided with a burst  
18  
19  
20  
21 265 phase of burst-suppression. All patients with SISA also produced acute post-hypoxic  
22  
23  
24 266 myoclonus and acute symptomatic seizures.  
25  
26

27  
28 267  
29  
30

#### 31 268 **4.1. Association with prognosis, acute post-hypoxic myoclonus and acute** 32 33 34 35 269 **symptomatic seizure** 36 37

38  
39 270 To the best of our knowledge, only two studies have reported infraslow activity  
40  
41  
42 271 in acute coma patients, and one study examined infraslow activity in adult patients with  
43  
44  
45 272 acute anoxic encephalopathy.<sup>15,18</sup> One of those studies showed infraslow activity in all 41  
46  
47  
48  
49 273 patients with acute anoxic encephalopathy, but the frequency of activity was 0.015-0.06  
50  
51  
52 274 Hz with the band-pass filter set at 0.01-0.1 Hz and continuous EEG recording for 2-3 days  
53  
54  
55  
56 275 after admission.<sup>15</sup> Frequency bands and occurrence rates thus differed from those in our  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 276 study. Another study examined SISA in acute hypoxic and ischemic encephalopathy of  
4  
5  
6  
7 277 neonates.<sup>18</sup> In that study, the duration of negative SISA was around 4 s, resembling that  
8  
9  
10 278 of our study, but the polarity derivation was opposite in the anterior and posterior  
11  
12  
13  
14 279 directions of the head.

15  
16  
17 280 As for the prognosis of patients, those two previous studies reached opposing  
18  
19  
20  
21 281 conclusions. In one study, overall outcomes were poor when the maximum amplitude of  
22  
23  
24 282 infraslow activity was  $>35 \mu\text{V}$ .<sup>15</sup> Conversely, high-amplitude SISA ( $>20 \mu\text{V}$ ) was  
25  
26  
27  
28 283 associated with favorable outcomes in the other study.<sup>18</sup> In the present study, patients with  
29  
30  
31  
32 284 SISA showed poor outcomes, but the number of those patients was small, and prognosis  
33  
34  
35 285 was also poor in patients without SISA. This may suggest that the presence of SISA  
36  
37  
38  
39 286 during burst phase is more specific for poor prognosis, and thus absence of SISA may  
40  
41  
42 287 suggest good prognosis. Nevertheless, we should remain rather cautious of prematurely  
43  
44  
45  
46 288 reaching for conclusions regarding the association between SISA and prognosis.

47  
48  
49 289 In our patients, the occurrence rate of acute post-hypoxic myoclonus and acute  
50  
51  
52  
53 290 symptomatic seizures were significantly higher in patients with SISA than in patients  
54  
55  
56 291 without SISA. Although the exact pathophysiology that leads to acute post-hypoxic  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 292 myoclonus is unclear and the myoclonus could potentially arise from a subcortical  
4  
5  
6  
7 293 structure such as the brainstem,<sup>28,34</sup> the myoclonus can also be associated with  
8  
9  
10 294 seizures.<sup>35,36</sup> We therefore evaluated acute post-hypoxic myoclonus in addition to acute  
11  
12  
13  
14 295 symptomatic seizures such as generalized tonic-clonic seizures.  
15

16  
17 296 Since SISA always occurred with burst-suppression in one-to-one  
18  
19  
20  
21 297 correspondence in the present study, burst-suppression itself may be associated with or  
22  
23  
24 298 share the pathophysiology of acute symptomatic seizures, and less information may be  
25  
26  
27  
28 299 contained in the findings of SISA. However, whether burst-suppression has an epileptic  
29  
30  
31 300 nature remains unclear, because volatile anesthetics induce burst-suppression after  
32  
33  
34  
35 301 counteracting status epilepticus.<sup>37</sup> Taken together, at least the combination of burst-  
36  
37  
38  
39 302 suppression and SISA is associated with acute post-hypoxic myoclonus or acute  
40  
41  
42 303 symptomatic seizures, particularly in critically ill patients with acute anoxic  
43  
44  
45  
46 304 encephalopathy. Although the exact reason for SISA coinciding with burst-suppression  
47  
48  
49  
50 305 was unclear from the present results, a previous study showed that infraslow activity (<0.1  
51  
52  
53 306 Hz) modulates cortical excitability.<sup>15</sup> We hypothesize that SISA may play a similar role.  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 307 In the present study, timing of EEG was different in each patient and thus  
4  
5  
6  
7 308 could have affected conventional EEG findings. EEGs from three patients were  
8  
9  
10 309 recorded at 8 days and those of two patients were recorded at 6 days after  
11  
12  
13 310 cardiopulmonary arrest. EEG findings in these patients were background suppression,  
14  
15  
16  
17 311 generalized periodic discharge and diffuse slowing in 3 patients, but none showed  
18  
19  
20  
21 312 SISA. The remaining patients (94.9%) underwent recording within 5 days from  
22  
23  
24 313 cardiopulmonary arrest. As for findings of SISA, we concluded that the timing of EEG  
25  
26  
27  
28 314 record did not affect our results.  
29  
30

31  
32 315

#### 33 34 35 316 **4.2. Generator mechanism for SISA**

36  
37  
38 317 Localized SISA recorded during epileptic seizures represented localized  
39  
40  
41  
42 318 activity of glial function, whereas activity in the present study was generalized.<sup>10,12</sup> Thus,  
43  
44  
45 319 some differences in generator mechanisms exist between these types of activity. The  
46  
47  
48  
49 320 generator mechanism of SISA in anoxic patients remains unclear, but the activity involves  
50  
51  
52  
53 321 inputs from the subcortical structures<sup>14</sup> in addition to non-neuronal sources such as glia.<sup>38</sup>  
54  
55  
56 322 In the thalamic relay nuclei, some cells have infraslow oscillations<sup>39</sup> and may represent  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 323 generator mechanisms of SISA, as seen in the present study.  
4  
5

6  
7 324 The onset time of SISA was also important for considering the generator  
8  
9  
10 325 mechanism. As shown in Table 3, EEGs were recorded in 5 of 6 patients presenting with  
11  
12  
13  
14 326 SISA within 1 day, while EEG in the remaining patient was recorded 3 days after  
15  
16  
17 327 cardiopulmonary arrest. If SISA was seen only early in the post-anoxia period, medication,  
18  
19  
20  
21 328 duration of anoxia, use of hypothermia, and co-existence of other disorders could be  
22  
23  
24 329 contributing factors. SISA occurring in the late phase of the post-anoxia period may  
25  
26  
27  
28 330 reflect glial participation, but medication, seizure control and so forth could also be  
29  
30  
31 331 contributing factors.  
32

33  
34  
35 332

### 36 37 38 333 **4.3. Clinical Utility** 39

40  
41  
42 334 Previous studies of infraslow activity or ictal slow shifts were recorded with a  
43  
44  
45 335 time constant of  $10\text{ s}^{10-12}$  or with a very low frequency setting for band-pass filtering.<sup>15,24-</sup>  
46  
47  
48  
49 336 <sup>26</sup> However, the present study successfully recorded SISA with a time constant of 2 s as a  
50  
51  
52  
53 337 clinically approved amplifier. If the duration or amplitude of infraslow activities is  
54  
55  
56 338 sufficiently high, activity can be recorded with a time constant of 2 s as a commonly used,  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 339 clinically approved amplifier.  
4  
5  
6

7 340  
8  
9

10 341 **4.4. Limitations**  
11  
12

13  
14 342 Several limitations must be considered in this study. First, the number of  
15  
16

17 343 patients with SISA was relatively small, impeding clarification of the relationship  
18  
19

20  
21 344 between SISA and prognosis. If patients without SISA during burst suppression had been  
22  
23

24 345 present, we could have evaluated the significance of SISA for defining prognosis.  
25  
26

27 346 However, the results may suggest that the presence of SISA during the burst phase shows  
28  
29

30  
31 347 high specificity (100%) for poor prognosis despite the small number of patients  
32  
33

34  
35 348 presenting SISA. The absence of SISA during burst suppression may also suggest good  
36  
37

38 349 prognosis. The present study was retrospective and this fact also limits the ability to reach  
39  
40

41  
42 350 conclusions regarding the clinical significance of SISA. Prospective studies are needed  
43  
44

45 351 as a step toward confirming the clinical meanings of SISA.  
46  
47

48  
49 352 Second, our recordings from EEG were not continuous and the interval between  
50  
51

52 353 EEG and cardiac arrest varied over the time course. We may have experienced sampling  
53  
54

55  
56 354 errors for SISA that would occur during continuous EEG recordings, because SISA was  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 355 often periodic.<sup>15</sup> That may be one reason explaining our low occurrence rate.  
4  
5

6  
7 356 Third, effects of treatments (propofol, midazolam and mild therapeutic  
8  
9  
10 357 hypothermia) may need to be considered. Although propofol could modulate EEG,  
11  
12  
13 358 propofol-induced EEG changes include increased amplitude of background activity,  
14  
15  
16  
17 359 anteriorization of the alpha rhythm,<sup>40</sup> and induction of burst-suppression. Burst-  
18  
19  
20  
21 360 suppression induced by propofol is morphologically heterogeneous.<sup>41</sup> In the present  
22  
23  
24  
25 361 study, among patients with burst-suppression, the only patient receiving propofol  
26  
27  
28 362 (Patient 2) showed identical burst-suppression. In addition, in a previous study,  
29  
30  
31 363 propofol-induced burst-suppression needed high-dose infusion (14-30 mg/kg/h),<sup>41</sup>  
32  
33  
34  
35 364 whereas the dose of propofol used for Patient 2 was relatively low (1 mg/kg/h).  
36  
37  
38  
39 365 Midazolam also induces burst-suppression and is often used for the treatment of  
40  
41  
42 366 refractory status epilepticus, but also needs high-dose infusion (0.19-0.22 mg/kg/h) for  
43  
44  
45 367 these effects.<sup>42,43</sup> Our Patients 1 and 6 received relatively smaller doses of midazolam  
46  
47  
48  
49 368 (0.03-0.04 mg/kg/h). Two of our six patients (Patients 5 and 6) with SISA were  
50  
51  
52  
53 369 receiving mild therapeutic hypothermia. The target temperature in the present study was  
54  
55  
56 370 34 °C, and achieving hypothermia to a level of 33-34 °C produces only marginal  
57  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3 371 alterations in EEG without changes in amplitude.<sup>44</sup> Deep hypothermia for surgery  
4  
5  
6  
7 372 requiring total circulatory arrest aims at achieving a rectal temperature <20 °C.<sup>45</sup> It was  
8  
9  
10 373 reported that only theta and beta activity increased and alpha activity decreased,<sup>44</sup> but  
11  
12  
13  
14 374 no reports appear to have described intermittent activity similar to SISA during mild  
15  
16  
17 375 hypothermia. As for slow waves during infusion of propofol and midazolam, delta  
18  
19  
20  
21 376 oscillations <4 Hz sometimes occur with alpha or beta oscillations,<sup>46,47</sup> but no obvious  
22  
23  
24 377 intermittent activity similar to SISA has been described. Although high-dose infusion of  
25  
26  
27  
28 378 propofol and midazolam could induce burst-suppression, less than one-quarter of a high  
29  
30  
31  
32 379 dose was actually administered to our patients. In addition to these lines of evidence,  
33  
34  
35 380 two patients in the present study showed SISA while receiving neither anesthesia nor  
36  
37  
38  
39 381 mild hypothermia. Taken together, propofol, midazolam and mild therapeutic  
40  
41  
42 382 hypothermia thus seem less likely to have modified burst-suppression or SISA, although  
43  
44  
45  
46 383 other conventional EEG findings could have been affected. However, we cannot  
47  
48  
49 384 completely assert that SISA has no association with drug effects, since SISA was not  
50  
51  
52  
53 385 reported in other situations.  
54  
55

56 386  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 **387 5. Conclusions**  
4  
5

6  
7 **388** In conclusion, SISA was identified in acute anoxic encephalopathy, although  
8  
9  
10 **389** the occurrence rate was low. Activity in the present study probably differs at least slightly  
11  
12  
13  
14 **390** from the infraslow activity reported in previous studies in terms of frequency and  
15  
16  
17  
18 **391** occurrence rate of activity. The differences in frequency and occurrence rate of activity  
19  
20  
21 **392** in the present study may be attributed to differences in methods of recording, particularly  
22  
23  
24  
25 **393** filter settings.  
26

27  
28 **394**  
29  
30

31 **395**  
32  
33

34  
35 **396 ACKNOWLEDGMENTS**  
36  
37

38  
39 **397**  
40  
41

42 **398** This work was partly supported by Grants-in-Aid for Scientific Research on Innovative  
43  
44  
45  
46 **399** Areas 17H05907, 15H05874, 17K09798 from the Japan Ministry of Education, Culture,  
47  
48  
49  
50 **400** Sports, Science and Technology (MEXT)  
51

52  
53 **401**  
54  
55

56 **402 Author contributions**  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 403 MT contributed to initiation and planning of the project, aided in the chart  
4  
5  
6  
7 404 review and data collection, wrote the first draft of the manuscript, edited subsequent drafts  
8  
9  
10 405 and created tables and figures. TH aided in the analysis of data from EEG and edited  
11  
12  
13  
14 406 manuscripts. TM aided in data analysis. MM contributed to the production of scripts for  
15  
16  
17 407 analyzing data from EEG. RM contributed to conception, design, analysis and  
18  
19  
20  
21 408 interpretation. HY, MK, NK provided additional patient information and aided in data  
22  
23  
24  
25 409 collection. RT contributed to conception and design. AI contributed to the initiation and  
26  
27  
28 410 conceptualization of the project, performed analysis of data from EEG, and edited the  
29  
30  
31 411 manuscript.

32  
33  
34  
35 412

36  
37  
38  
39 413  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

414 **References**

- 415 1. Feingold P, Mina MJ, Burke RM, et al. Long-term survival following in-hospital  
416 cardiac arrest: A matched cohort study. *Resuscitation* 2016;99:72-78.
- 417 2. Zandbergen EG, de Haan RJ, Stoutenbeek CP, Koelman JH, Hijdra A. Systematic  
418 review of early prediction of poor outcome in anoxic-ischaemic coma. *Lancet*  
419 1998;352:1808-1812.
- 420 3. Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-  
421 hospital cardiac arrest with induced hypothermia. *N Engl J Med* 2002;346:557-563.
- 422 4. Wijdicks EF, Hijdra A, Young GB, Bassetti CL, Wiebe S; Quality Standards  
423 Subcommittee of the American Academy of Neurology. Practice parameter: Prediction  
424 of outcome in comatose survivors after cardiopulmonary resuscitation (an evidence-based  
425 review): report of the Quality Standards Subcommittee of the American Academy of  
426 Neurology. *Neurology* 2006; 67:203-210.
- 427 5. Westhall E, Rossetti AO, van Rootselaar AF, et al. Standardized EEG interpretation  
428 accurately predicts prognosis after cardiac arrest. *Neurology* 2016;86:1482-1490.
- 429 6. Hofmeijer J, Beernink T, Bosch FH, et al. Early EEG contributes to multimodal

1  
2  
3 430 outcome prediction of postanoxic coma. *Neurology* 2015;85:137-143.  
4  
5

6  
7 431 7. Bordey A, Lyons SA, Hablitz JJ, Sontheimer H. Electrophysiological characteristics  
8  
9  
10 432 of reactive astrocytes in experimental cortical dysplasia. *J. Neurophysiol.* .  
11  
12  
13  
14 433 2001;85:1719–31.  
15

16  
17 434 8. Tian GF, Azmi H, Takano T, et al. An astrocytic basis of epilepsy. *Nat. Med.*  
18  
19  
20  
21 435 2005;11:973-981.  
22

23  
24 436 9. Voipio J, Tallgren P, Heinonen E, Vanhatalo S, Kaila K. Millivolt-scale DC shifts in  
25  
26  
27  
28 437 the human scalp EEG: evidence for a nonneuronal generator. *J. Neurophysiol.*  
29  
30  
31 438 2003;89:2208-14.  
32

33  
34  
35 439 10. Ikeda A, Taki W, Kunieda T, et al. Focal ictal direct current shifts in human epilepsy  
36  
37  
38  
39 440 as studied by subdural and scalp recording. *Brain* 1999;122:827-838.  
40

41  
42 441 11. Imamura H, Matsumoto R, Inouchi M,. Ictal wideband ECoG: Direct comparison  
43  
44  
45  
46 442 between ictal slow shifts and high frequency oscillations. *Clin. Neurophysiol*  
47  
48  
49 443 2011;1122:1500-1504.  
50

51  
52  
53 444 12. Kanazawa K, Matsumoto R, Imamura H, et al. Intracranially recorded ictal direct  
54  
55  
56 445 current shifts may precede high frequency oscillations in human epilepsy. *Clin.*  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 446 *Neurophysiol.* 2015;126:47-59.  
4  
5  
6

7 447 13. Drenckhahn C, Winkler MK, Major S, et al. Correlates of spreading depolarization in  
8  
9  
10 448 human scalp electroencephalography. *Brain* 2012;135:853-868.  
11  
12

13  
14 449 14. Vanhatalo S, Palva JM, Holmes MD, Miller JW, Voipio J, Kaila K. Infraslow  
15  
16  
17 450 oscillations modulate excitability and interictal epileptic activity in the human cortex  
18  
19  
20  
21 451 during sleep. *Proc. Natl. Acad. Sci. USA* 2004;101:5053-5057.  
22  
23

24 452 15. van Putten MJ, Tjepkema-Cloostermans MC, Hofmeijer J. Infraslow EEG activity  
25  
26  
27 453 modulates cortical excitability in postanoxic encephalopathy. *J. Neurophysiol.*  
28  
29  
30  
31 454 2015;113:3256-3267.  
32  
33

34  
35 455 16. Aladjalova N, Infra-slow rhythmic oscillations of the steady potential of the cerebral  
36  
37  
38 456 cortex. *Nature.* 1957; 179: 957-959.  
39  
40

41  
42 457 17. Vanhatalo S, Voipio J, Kaila K. Full-band EEG (FbEEG): an emerging standard in  
43  
44  
45 458 electroencephalography. *Clin Neurophysiol.* 2005;116:1-8.  
46  
47  
48

49 459 18. Thordstein M, Löfgren N, Flisberg A, Bågenholm R, Lindecrantz K, Kjellmer I.  
50  
51  
52 460 Infraslow EEG activity in burst periods from post asphyctic full term neonates. *Clin.*  
53  
54  
55 461 *Neurophysiol.* 2005;116:1501-1506.  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3 462 19. Rodin E, Constantino T, van Orman C, et al. Optimal evaluation of digital electro-  
4  
5  
6  
7 463 encephalograms. *Clin EEG Neurosci* 2006;37:178–189.  
8  
9  
10 464 20. Rodin E, Constantino T, van Orman C, House P. EEG infraslow activity in absence  
11  
12  
13  
14 465 and partial seizures. *Clin EEG Neurosci* 2008;39:12–19.  
15  
16  
17 466 21. Rodin E, Modur P. Ictal intracranial infraslow EEG activity. *Clin Neurophysiol*  
18  
19  
20  
21 467 2008;119:2188–2200.  
22  
23  
24 468 22. Rampp S, Stefan H. Ictal onset baseline shifts and infraslow activity. *J. Clin.*  
25  
26  
27  
28 469 *Neurophysiol.* 2012;29:291-297.  
29  
30  
31 470 23. Rodin E, Funke M. Cerebral Electromagnetic activity in the subdelta range. *J. Clin.*  
32  
33  
34  
35 471 *Neurophysiol.* 2006;23:238-244.  
36  
37  
38 472 24. Constantino T, Rodin E. Peri-ictal and interictal, intracranial infraslow activity. *J.*  
39  
40  
41  
42 473 *Clin. Neurophysiol.* 2012;29:298-308.  
43  
44  
45 474 25. Rodin E, Constantino T, Bigelow J. Ictal infraslow activity in patients with  
46  
47  
48  
49 475 epilepsy. *Clin Neurophysiol* 2014;125:919–929.  
50  
51  
52 476 26. Thompson SA, Krishnan B, Gonzalez-Martinez J, et al. Ictal infraslow activity in  
53  
54  
55  
56 477 stereoelectroencephalography: Beyond the “DC shift”. *Clin Neurophysiol.*  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 478 2016;127:117-128.  
4  
5

6  
7 479 27. Wennberg R, Steriade C, Chen R, Andrade D. Frontal SISA marks the motor spasms  
8  
9  
10 480 of anti-LGI1 encephalitis. *Clin Neurophysiol.* 2018;129:59-68.  
11  
12

13  
14 481 28. Gupta H, Caviness J. Post-hypoxic myoclonus: Current concepts, Neurophysiology,  
15  
16  
17 482 and Treatment. *Tremor Other Hyperkinet Mov.* 2016;6:409.  
18  
19

20  
21 483 29. Jennett B, Bond M. Assessment of outcome after severe brain damage. *Lancet*  
22  
23  
24 484 1975;1:480-484.  
25  
26

27  
28 485 30. Cummins R, Chamberlain DA, Abramson NS, et al. Recommended guidelines for  
29  
30  
31 486 uniform reporting of data from out-of-hospital cardiac arrest: the Utstein Style A  
32  
33  
34  
35 487 statement for health professionals from a task force of the American Heart Association,  
36  
37  
38 488 the European Resuscitation Council, the Heart and Stroke Foundation of Canada, and the  
39  
40  
41  
42 489 Australian Resuscitation Council. *Circulation.* 1991;84:960-975.  
43  
44

45  
46 490 31. Cloostermans MC, van Meulen FB, Eertman CJ, Hom HW, van Putten MJ.  
47  
48  
49 491 Continuous electroencephalography monitoring for early prediction of neurological  
50  
51  
52 492 outcome in postanoxic patients after cardiac arrest: a prospective cohort study. *Crit.*  
53  
54  
55  
56 493 *Care Med.* 2012;40:2867-2875.  
57  
58  
59  
60  
61  
62  
63  
64  
65



- 1  
2  
3 494 32. Hirsch LJ, LaRoche SM, Gaspard N, et al. American Clinical Neurophysiology  
4  
5  
6  
7 495 Society's Standardized Critical Care EEG Terminology: 2012 version. *J. Clin.*  
8  
9  
10 496 *Neurophysiol.* 2013;30:1-27.
- 11  
12  
13  
14 497 33. Hofmeijer J, Tjepkema-Cloostermans MC, van Putten MJ. Burst-suppression with  
15  
16  
17 498 identical bursts: A distinct EEG pattern with poor outcome in postanoxic coma. *Clin.*  
18  
19  
20  
21 499 *Neurophysiol.* 2014;125:947-954.
- 22  
23  
24 500 34. Kakisaka Y, Haginoya K, Togashi N, et al. Neonatal-onset brainstem reticular reflex  
25  
26  
27 501 myoclonuss following a prenatal brain insult: generalized myoclonic jerk and a brainstem  
28  
29  
30  
31 502 lesion. *Tohoku J. Exp. Med* 2007;211:303-308.
- 32  
33  
34  
35 503 35. Hallet M. Physiology of human posthypoxic myoclonus. *Mov Disord* 2000;15  
36  
37  
38 504 (suppl.1)
- 39  
40  
41  
42 505 36. Wijdicks EF, Parisi JE, Sharbrough FW. Prognostic value of myoclonuss status in  
43  
44  
45 506 comatose survivors of cardiac arrest. *Ann Neurol* 1994;35:239-243.
- 46  
47  
48  
49 507 37. Amzica F. Basic physiology of burst-suppression. *Epilepsia* 2009;50:38-39.
- 50  
51  
52  
53 508 38. Amzica F, Steriade M. Neuronal and glial membrane potentials during sleep and  
54  
55  
56 509 paroxysmal oscillations in the neocortex. *J. Neurosci.* 2000;20:6648-6665.  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3 510 39. Hughes SW, Lorincz ML, Parri HR, Crunelli V. Infra-slow (<0.1 Hz) oscillations in  
4  
5  
6  
7 511 thalamic relay nuclei: basic mechanisms and significance to health and disease states.  
8  
9  
10 512 *Brain* 2011;193:145-162.  
11  
12  
13  
14 513 40. Hindriks R, van Putten MJ. Meanfield modeling of propofol-induced changes in  
15  
16  
17 514 spontaneous EEG rhythms. *Neuroimage* 2012;60:2323–2334.  
18  
19  
20  
21 515 41. Reddy RV, Moorthy SS, Mattice T, Dierdorf SF, Deitch RD Jr. An  
22  
23  
24 516 electroencephalographic comparison of effects of propofol and methohexital.  
25  
26  
27 517 *Electroencephalogr. Clin. Neurophysiol.* 1992;83:162-168.  
28  
29  
30  
31 518 42. Claassen, J, Hirsch, LJ, Emerson, RG, Bates JE, Thompson TB, Mayer SA.  
32  
33  
34  
35 519 Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive  
36  
37  
38 520 status epilepticus. *Neurology* 2001; 57:1036-1042.  
39  
40  
41  
42 521 43. Parent JM, Lowenstein DH. Treatment of refractory generalized status epilepticus  
43  
44  
45 522 with continuous infusion of midazolam. *Neurology* 1994;44:1837–1840.  
46  
47  
48  
49 523 44. Fitzgibbon T, Hayward JS, Walker D. EEG and visual evoked potentials of  
50  
51  
52 524 conscious man during moderate hypothermia. *Electroencephalogr Clin Neurophysiol.*  
53  
54  
55 525 1984; 58:48-54.  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 526 45. Stecker MM, Cheung AT, Pochettino A, et al. Deep hypothermic circulatory arrest:  
4  
5  
6  
7 527 II. Changes in electroencephalogram and evoked potentials during rewarming. Ann  
8  
9  
10 528 Thorac Surg. 2001;71:22-28.

11  
12  
13  
14 529 46. Purdon PL, Sampson A, Pavone KJ, Brown EN. Clinical electroencephalography for  
15  
16  
17 530 Anesthesiologists: Part I: Background and basic signatures. Anesthesiology.  
18  
19  
20  
21 531 2015;123:937-960.

22  
23  
24 532 47. Feshchenko VA, Veselis RA, Reinsel RA. Comparison of the EEG effects of  
25  
26  
27 533 midazolam, thiopental, and propofol: the role of underlying oscillatory systems.  
28  
29  
30  
31 534 Neuropsychobiology. 1997;35:211-220.

32  
33  
34  
35 535

36  
37  
38  
39 536 **Figure legends**

40  
41  
42 537 Figure 1. Representative waveforms in referential montage and time-frequency analysis  
43  
44  
45 538 of SISA in Patient 2.

46  
47  
48  
49 539 A) Activity with time constant of 0.1 s. B) Activity with time constant of 2 s. C) Time-  
50  
51  
52 540 frequency analysis and waveforms of SISA.

53  
54  
55  
56 541 SISA is more clearly delineated with a time constant of 2 s (B, black line) than with a  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

542 time constant of 0.1 s. Time-frequency analysis (0-100Hz) showed increased power of  
543 low-frequency band and no electromyographic artifact. SISA was evaluated in a  
544 monopolar montage F3-A1 and F4-A2 with high-cut filter 1Hz and low-cut filter  
545 0.08Hz.

Figure 1.




Figure 1.






Table 1. Patient characteristics

Patients, n	98
Men, n	71 (72.4%)
Age, y	65.7 ± 15.4
Initial cardiac rhythm	
Pulseless electrical activity	29 (29.6%)
Asystole	32 (32.6%)
VF	17 (17.3%)
Time difference from cardiac arrest to resuscitation, min	22.3 ± 18.3
Inhospital	36 (36.7%)
No abnormality in brain CT/MRI	42 (42.9%)
Acute symptomatic seizure	42 (42.9%)
Myoclonic	37 (37.8%)
Generalized tonic clonic	2 (2.0%)
Both	3 (3.1%)
Sedation	
Propofol	26 (26.5%)
Midazolam	16 (16.3%)
Fentanyl	15 (15.3%)
Hypothermia, n	29 (29.6%)
Neurological outcome	
Good (CPC 1-2)	6 (6.1%)
Poor (CPC 3-4)	38 (38.8%)
Death (CPC 5)	54 (55.1%)
EEG recording, day	2.4 ± 1.6
	(from cardiac arrest)

CPC: Cerebral Performance Category

1: no disability, 2: moderate disability, 3: severely disabled, 4: comatose,  
5: deceased



Table 2. EEG findings

EEG findings	Patient number (n = 98)	Prognosis (mild - severe - deceased)
Electrocerebral inactivity*	5	0 - 1 - 4
Background suppression*	22	1 - 11 - 10
Burst-suppression*	6	0 - 3 - 3
Periodic discharge*	15	0 - 8 - 7
Delta coma	12	1 - 3 - 8
Alpha coma	2	2 - 0 - 0
Diffuse slowing	34	1 - 17 - 16
Spindle coma	1	1 - 0 - 0
Inconclusive (due to artifact)	1	1

\* EEG findings suggestive of poor prognosis



Table 3. Characteristics of patients with SISA

Patient No./ Sex/Age	CPA time (min)	Onset	Initial Rhythm	Sedation	Mild Hypothermia	Neuroimaging	EEG Recordings (day)	Acute post-Hypoxic Myoclonus/ Acute Symptomatic Seizure	Prognosis	Identical Burst
1/M/61	20	Out of hospital	Asystole	Midazolam (0.04mg /kg/hr)		Basal ganglia Obscure	1	Myoclonus	Death (day 12)	Not Identical
2/F/83	12	Inhospital	Asystole	Propofol (1mg /kg/hr)		Basal ganglia Obscure	0.4	Myoclonus + GTCS	CPC 5	Identical
3/M/85	20	Out of hospital	Asystole	None		Normal	1	Myoclonus	Death (day 8)	Not Identical
4/F/62	30	Inhospital	Asystole	None		Normal	1	Myoclonus	Death (day 2)	Identical
5/M/37	23	Out of hospital	Unknown	None	✓	Diffuse Ischemia	1	GTCS	CPC 5	Not Identical
6/F/53	Unknown	Out of hospital	Unknown	Midazolam (0.03mg /kg/hr)	✓	Normal	3	Myoclonus	CPC 5	Identical

Table 4. Characteristics of SISA (means  $\pm$  SD)

Patient No./ Sex/Age	Interval (s)	Duration (s)	Burst phase (Hz)	Amplitude ( $\mu$ V)
1/M/61	44.1 $\pm$ 10.0	6.0 $\pm$ 1.3	4.8 $\pm$ 0.5	174.9 $\pm$ 49.0
2/M/85	8.7 $\pm$ 0.5	5.1 $\pm$ 1.9	5.1 $\pm$ 1.9	74.3 $\pm$ 20.9
3/F/83	17.7 $\pm$ 4.9	6.3 $\pm$ 0.4	7.1 $\pm$ 1.1	334.8 $\pm$ 150.0
4/F/62	19.3 $\pm$ 5.6	5.4 $\pm$ 0.2	5.3 $\pm$ 0.2	160.7 $\pm$ 8.5
5/M/37	16.6 $\pm$ 5.4	4.2 $\pm$ 1.3	5.5 $\pm$ 2.0	41.3 $\pm$ 6.7
6/F/53	7.7 $\pm$ 2.5	5.2 $\pm$ 1.4	8.7 $\pm$ 2.4	361.8 $\pm$ 37.1

Table 5. Occurrence rate of acute post-hypoxic myoclonus or acute symptomatic seizure and rate of poor outcome

	Myoclonus or Seizure +	Myoclonus or Seizure -
SISA +	6	0
SISA -	38	54

P = 0.0067 (Fisher exact test)

Sensitivity = 13.6%, Specificity = 100%

	Poor prognosis	Good prognosis
SISA +	6	0
SISA -	86	6

P > 0.05 (Fisher exact test)

Sensitivity = 6.5%, Specificity = 100%